• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma ADR (NQ: ASND )

    144.62 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6
    Open 144.62
    Bid (Size) 58.14 (1)
    Ask (Size) 149.00 (1)
    Prev. Close 144.62
    Today's Range 144.62 - 144.62
    52wk Range 85.28 - 161.00
    Shares Outstanding 57,152,295
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Looking Into Ascendis Pharma's Recent Short Interest
    Via Benzinga
    BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
    BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
    Via Benzinga

    Performance

    YTD
    +13.40%
    +13.40%
    1 Month
    +4.46%
    +4.46%
    3 Month
    +7.94%
    +7.94%
    6 Month
    -4.84%
    -4.84%
    1 Year
    +58.70%
    +58.70%

    More News

    Read More
    Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
    Via Benzinga
    Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Via Benzinga
    $100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today
    Via Benzinga
    $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
    Via Benzinga
    Crude Oil Surges Over 1%; Instil Bio Shares Plunge
    Via Benzinga
    Exposures Fossil Fuels
    Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year
    Via Benzinga
    Exposures Product Safety
    Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
    Via Investor's Business Daily
    Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Here's How Much $1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
    Via Benzinga
    Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
    Via Benzinga
    If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
    Via Benzinga
    Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
    Via Benzinga
    Why Ascendis Pharma Stock Tumbled by 11% Today
    Via The Motley Fool
    Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout
    Via Investor's Business Daily
    Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
    Via Benzinga
    Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
    Via Benzinga
    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
    Via Benzinga
    Exposures Product Safety
    Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug
    Via Investor's Business Daily
    Exposures Product Safety
    Macy's, Ascendis Pharma And 3 Stocks To Watch Heading Into Friday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.